• Je něco špatně v tomto záznamu ?

Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate

O. Fiala, P. Hošek, H. Korunková, M. Hora, J. Kolář, O. Šorejs, O. Topolčan, J. Filipovský, V. Liška, M. Santoni, S. Buti, J. Fínek

. 2024 ; 13 (1) : e6853. [pub] 20240102

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24020053

Grantová podpora
FN 00669806 Institutional Research Fund of University Hospital Pilsen
856620 European Union's Horizon 2020
LX22NPO5102 European Union - Next Generation EU
Charles University Research Fund

BACKGROUND: The introduction of novel hormonal therapies represented by enzalutamide (ENZ) and abiraterone acetate (ABI) has reached a great progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The majority of mCRPC patients are elderly suffering from chronic co-morbidities requiring use of various concomitant medications. In the present study, we focused on impact of concomitant antihypertensive medication on the outcomes of mCRPC patients treated with ENZ or ABI. METHODS: In total, 300 patients were included and their clinical data were retrospectively analyzed. RESULTS: Angiotensin-converting enzyme inhibitors (ACEIs) represented the only concomitant medication significantly associated with survival. The median radiographic progression-free survival (rPFS) and overall survival (OS) for patients using ACEIs were 15.5 and 32.3 months compared to 10.7 and 24.0 months for those not using ACEIs (p = 0.0053 and p = 0.0238, respectively). Cox multivariable analysis revealed the use of ACEIs a significant predictive factor for both rPFS (HR = 0.704, p = 0.0364) and OS (HR = 0.592, p = 0.0185). CONCLUSION: The findings of this study suggest an association between the concomitant use of ACEIs and longer survival of mCRPC patients receiving ENZ or ABI therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24020053
003      
CZ-PrNML
005      
20241024110907.0
007      
ta
008      
241015s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cam4.6853 $2 doi
035    __
$a (PubMed)38164124
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Fiala, Ondřej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $1 https://orcid.org/0000000240967385
245    10
$a Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate / $c O. Fiala, P. Hošek, H. Korunková, M. Hora, J. Kolář, O. Šorejs, O. Topolčan, J. Filipovský, V. Liška, M. Santoni, S. Buti, J. Fínek
520    9_
$a BACKGROUND: The introduction of novel hormonal therapies represented by enzalutamide (ENZ) and abiraterone acetate (ABI) has reached a great progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The majority of mCRPC patients are elderly suffering from chronic co-morbidities requiring use of various concomitant medications. In the present study, we focused on impact of concomitant antihypertensive medication on the outcomes of mCRPC patients treated with ENZ or ABI. METHODS: In total, 300 patients were included and their clinical data were retrospectively analyzed. RESULTS: Angiotensin-converting enzyme inhibitors (ACEIs) represented the only concomitant medication significantly associated with survival. The median radiographic progression-free survival (rPFS) and overall survival (OS) for patients using ACEIs were 15.5 and 32.3 months compared to 10.7 and 24.0 months for those not using ACEIs (p = 0.0053 and p = 0.0238, respectively). Cox multivariable analysis revealed the use of ACEIs a significant predictive factor for both rPFS (HR = 0.704, p = 0.0364) and OS (HR = 0.592, p = 0.0185). CONCLUSION: The findings of this study suggest an association between the concomitant use of ACEIs and longer survival of mCRPC patients receiving ENZ or ABI therapy.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a nádory prostaty rezistentní na kastraci $x farmakoterapie $x mortalita $x patologie $7 D064129
650    12
$a fenylthiohydantoin $x terapeutické užití $7 D010669
650    12
$a abirateron $x terapeutické užití $x aplikace a dávkování $7 D000069501
650    _2
$a senioři $7 D000368
650    12
$a nitrily $x terapeutické užití $7 D009570
650    12
$a benzamidy $x terapeutické užití $7 D001549
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a antihypertenziva $x terapeutické užití $7 D000959
650    _2
$a lidé středního věku $7 D008875
650    _2
$a výsledek terapie $7 D016896
650    _2
$a inhibitory ACE $x terapeutické užití $7 D000806
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x škodlivé účinky $7 D000971
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hošek, Petr $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Korunková, Hana $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Hora, Milan $u Department of Urology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic $1 https://orcid.org/0000000250613687 $7 mzk2004258359
700    1_
$a Kolář, Jiří $u Department of Urology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Šorejs, Ondřej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Topolčan, Ondřej $u Department of Immunochemistry Diagnostics, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Filipovský, Jan $u 2nd Department of Internal Medicine, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Liška, Václav $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Department of Surgery, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Santoni, Matteo $u Oncology Unit, Macerata Hospital, Macerata, Italy
700    1_
$a Buti, Sebastiano $u Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy $u Oncology Unit, University Hospital of Parma, Parma, Italy $1 https://orcid.org/0000000308760226
700    1_
$a Fínek, Jindřich $u Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic
773    0_
$w MED00181704 $t Cancer medicine $x 2045-7634 $g Roč. 13, č. 1 (2024), s. e6853
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38164124 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110901 $b ABA008
999    __
$a ok $b bmc $g 2202347 $s 1232026
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 13 $c 1 $d e6853 $e 20240102 $i 2045-7634 $m Cancer medicine $n Cancer Med $x MED00181704
GRA    __
$a FN 00669806 $p Institutional Research Fund of University Hospital Pilsen
GRA    __
$a 856620 $p European Union's Horizon 2020
GRA    __
$a LX22NPO5102 $p European Union - Next Generation EU
GRA    __
$p Charles University Research Fund
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace